Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvastatin + Axitinib + Toripalimab in Advanced Renal Cell Carcinoma
NCT07630363Phase 2Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- May 2026
- Primary completion
- Mar 2028
- Countries
- 1
01
Overview
Phase 2, open-label trial of atorvastatin in renal cell carcinoma (RCC) (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Objective Response Rate up to 24 months. Planned start May 2026; status: not yet recruiting.
02
Drugs
atorvastatin
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT07630363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07630363.